SPRO Earnings — Spero Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
SPRO — Spero Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$2.90
Market Cap$169.7M
P/E11.1
52W Range$1.80 – $3.22
Next Earnings2026-08-11
About Spero Therapeutics, Inc. Common Stock
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
